Fut, nem toboroz2. fázis
Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients
A legfontosabb adatok
- Ki végzi
- Assistance Publique Hopitaux De Paris
- Hol
- Franciaország19 helyszín, 1 országbanVálassz országot a helyszínekhez
- Állapot
- Fut, nem toboroz
- Fázis
- 2. fázis
- Résztvevők
- 148 fő, tervezett
- Kezdés
- 2020. júl. 29.
- Várható befejezés
- 2028. júl. 29.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2025. február 26.
Ki vehet részt
- Életkor
- 18 év – 64 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Patients aged ≥ 18 years
- First episode of Minimal Change Nephrotic Syndrome defined as albumin level < 30 g/L and urine protein/creatinine ratio (UPCR) ≥ 300mg/mmol, OR
- Biopsy-proven MCNS defined on renal biopsy examination by the presence of minimal change glomerular lesions and absence of segmental sclerosis by light microscopy, negative immunofluorescence, or presence of IgM deposits into the mesangium
- Signed informed consent to participate in the study
- Patients who are affiliated with the French health care system
Ki nem vehet részt
- Previous administration of Rituximab therapy
- Patients with a known allergy to steroid and its excipients or to Rituximab and its excipients or to acetaminophen and its excipients or to cetirizine and its excipients or to protein of murine origin
- Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol
- Females of childbearing potential who don’t have an effective method of birth control during the study and during the next 12 months after treatment stop; Women who are pregnant (positive βHCG at inclusion), or who plan to become pregnant whilst in the trial; Patient started on oral steroid therapy according to protocol dosage (1mg/kg) more than 4 weeks ago; Breastfeeding women; Severe heart failure (New York Heart Association Class III and IV) or severe or uncontrolled cardiac disease; Patients who participate simultaneously in another interventional trial; Patients not willing or able to comply with the protocol requirements; Patients who are under tutorship or curatorship; MCNS resulting from a secondary process (lymphoid disorders or malignant disease) or potentially related to treatment known to be associated with MCNS occurrence (Lithium, Interferon, non-steroidal anti-inflammatory drugs); Patients with acute infections or chronic active infections; Positive serological screening test for HIV, B or C hepatitis; Positive immunological tests for antinuclear and anti-DNA antibodies; Usual contraindication to steroid or Rituximab; Immunosuppressed patients, patients with a severe immune deficit; Patients with hypersensitivity to a monoclonal antibody or biological agents
- Patients who have white blood cell count ≤4,000/mm3
- Patients who have platelet count ≤100,000/mm3
- Patient who have haemoglobin <9g/dL
- Patients who SGOT or SGPT or bilirubin level greater than 3 times the upper limit of normal
- Patients who have serum creatinine level >150 µmol/l,
- Patients with active cancer or recent cancer (<5 years)
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To demonstrate, from initial episode of MCNS in adults, once complete remission occurred, the efficacy of Rituximab (two injections separated by one week 375mg/m2, with definitive steroids withdrawal after 9 weeks of treatment) to prevent relapse after 12 months of follow-up
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- RIFIREINS. Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients
- Publikációk
- A New Hope for Treating Podocytopathies: Emerging Role of Anti-Nephrin Antibody.Clinical journal of the American Society of Nephrology : CJASN, 2026
- Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies.Journal of the American Society of Nephrology : JASN, 2025
- Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany), 2022
- A regiszteradat frissítve
- 2025. február 26.